SABS Strangle Strategy
SABS (SAB Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SABS (SAB Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $36.3M, a beta of 0.55 versus the broader market, a 52-week range of 1.67-6.6, average daily share volume of 864K, a public-listing history dating back to 2021, approximately 86 full-time employees. These structural characteristics shape how SABS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.55 indicates SABS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on SABS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current SABS snapshot
As of June 30, 2026, spot at $3.90, ATM IV 241.50%, IV rank 46.68%, expected move 69.24%. The strangle on SABS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on SABS specifically: SABS IV at 241.50% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 69.24% (roughly $2.70 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SABS expiries trade a higher absolute premium for lower per-day decay. Position sizing on SABS should anchor to the underlying notional of $3.90 per share and to the trader's directional view on SABS stock.
SABS strangle setup
The SABS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SABS near $3.90, the first option leg uses a $4.10 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SABS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SABS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.10 | N/A |
| Buy 1 | Put | $3.70 | N/A |
SABS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SABS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SABS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SABS
Strangles on SABS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SABS chain.
SABS thesis for this strangle
The market-implied 1-standard-deviation range for SABS extends from approximately $1.20 on the downside to $6.60 on the upside. A SABS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SABS IV rank near 46.68% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SABS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SABS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SABS-specific events.
SABS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SABS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SABS alongside the broader basket even when SABS-specific fundamentals are unchanged. Always rebuild the position from current SABS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SABS?
- A strangle on SABS is the strangle strategy applied to SABS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SABS stock trading near $3.90, the strikes shown on this page are snapped to the nearest listed SABS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SABS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SABS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 241.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SABS strangle?
- The breakeven for the SABS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SABS market-implied 1-standard-deviation expected move is approximately 69.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SABS?
- Strangles on SABS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SABS chain.
- How does current SABS implied volatility affect this strangle?
- SABS ATM IV is at 241.50% with IV rank near 46.68%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.